1. Scrip
  2. >>COVID-19

Coronavirus Update: Remdesivir Fast-Tracked, GSK's Shingrix Hit Hard By Lockdown

Plus J&J Expands Manufacturing Capacity

 
• By Scrip Team

Results from the first major trial of remdesivir are positive, but fail to show clear mortality benefit - making its forthcoming approval just the first step towards winning the war on COVID-19.

Hahn, White House
FDA Commissioner Stephen Hahn speaking at the White House coronavirus briefing • Source: The White House

Encouraging trial data from a major placebo-controlled trial of Gilead Sciences Inc.'s remdesivir will be enough for regulators in the US and EU to fast-track its approval, though it is clear the drug is far from a miracle cure for COVID-19.

Results from the ACTT adaptive trial released on 29 April showed that the antiviral drug had a significant effect in treating the virus, helping hospitalized patients recover from their illness in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’